



ORAL & FACIAL SURGERY SPECIALISTS

FELIX SIM BDS(HONS), MBBS, MFDS(ENG), FRACDCS(OMS)

TRACEY HUNTLEY MDSc(MELB), FRACDS(OMS)

SHIVA SUBRAMANIAM MBBS, BDS, FRCS(OMS), FRACDS(OMS)


JARREN WANG MBBS, BDS, FRACDS(OMS)

Guide for extractions in patients on anti-resorptive medications

- Risk of MRONJ based on type of medication and indication (cases per 10,000 patients)

Medication	Indication – Osteoporosis	Indication – Cancer
Oral bisphosphonate(BP) < 4 years	10	N/A
Oral bisphosphonate(BP) > 4 years	21	N/A
Denosumab (<i>Prolia, Aredia</i>)	4	70-190
IV BP (<i>Zometa</i>)	1.7	110

- Guidelines for patients requiring extraction¹



- Is CTX useful in predicting risk of MRONJ ?

NO - BP therapy commonly lowers CTX to <0.15 ng/ml; however, ONJ is rare.

Low CTX is simply a reflection of the pharmacological effects of antiresorptive therapy and is not useful in identifying individuals at risk for ONJ.²

- References

1. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2022 Update. *Journal of Oral and Maxillofacial Surgery*. 2022;80(05):920-943.



T

(03) 9731 8700



F

(03) 9731 1999



E

admin@ofsspecialists.com.au



W

www.ofsspecialists.com.au